跳至主要内容
临床试验/EUCTR2020-001194-69-ES
EUCTR2020-001194-69-ES进行中(未招募)1 期

Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) - MEFLOCOVID-19

Félix Gutiérrez Rodero0 个研究点目标入组 200 人开始时间: 2020年4月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • People in close contact with adults diagnosed with COVID-19 who sign the informed consent. Close contact is defined as those who live at home with an infected person, who have had intimate relationships or whose job is less than two meters from the infected person.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 100
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 100

排除标准

  • -Patients <18 years.
  • -Patients with symptoms suggestive of SARS-CoV-2 infection.
  • -Women who are pregnant or who intend to become pregnant for the next three months after taking the drug.
  • -Patients allergic to mefloquine or other quinine or quinidine-type medications.
  • -Patients with a neurological history (seizures, epilepsy, etc.).
  • -Patients with a previous history of psychiatric illnesses (depression, anxiety, suicide attempt).
  • -Patients with cardiac pathologies or relevant chronic diseases that in the judgment of the clinician recommend the non-inclusion of the patient in the study.
  • -Patients in treatment with other medications such as valproic acid, antiarrhythmics, antihistamines H1, beta-blockers, calcium channel blockers, chloroquine, halofantrine, phenothiazines, quinidine and quinine.

研究者

发起方
Félix Gutiérrez Rodero

相似试验